Panitumumab in metastatic colorectal cancer.
Wisinski
Kari B
KB
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Ill, USA.
Mulcahy
Mary F
MF
Benson
Al B
AB
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D009944:Organoplatinum Compounds; D004815:Epidermal Growth Factor; D000077544:Panitumumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin